Discovery of a novel Fam20C inhibitor for treatment of triple-negative breast cancer

被引:1
作者
Lu, Yingying [1 ]
Zhen, Yongqi [1 ,2 ,3 ]
Li, Zhijia [1 ]
Luo, Boqin [1 ]
Yin, Bo [1 ]
Zhang, Lan [1 ]
机构
[1] Southwest Jiaotong Univ, Sichuan Engn Res Ctr Biomimet Synth Nat Drugs, Sch Life Sci & Engn, Chengdu 610031, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Fam20C; Small-molecule inhibitor; TNBC; Antitumor; Migration; Apoptosis; APOPTOSIS;
D O I
10.1016/j.ijbiomac.2024.138398
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sequence similarity 20 family member C (Fam20C), a Golgi casein kinase, has a gradually elucidated mechanism in triple-negative breast cancer (TNBC) and is considered a possible target for therapeutic intervention. In this study, we combined virtual screening and chemical synthesis methods to obtain a new small-molecule Fam20C inhibitor, compound 5k, which possesses desirable kinase inhibitory activity against Fam20C and significant anti-proliferative activity against MDA-MB-231 and BT-549 cells. Subsequently, cellular thermal shift assay (CETSA), molecular docking, and molecular dynamics (MD) simulations revealed that compound 5k binds to Fam20C. Moreover, compound 5k showed favorable antitumor efficacy in TNBC cells and xenograft models by promoting apoptosis and inhibiting migration. Mechanistically, compound 5k can inhibit the proliferation, promote apoptosis, and inhibit migration of TNBC cells by targeting Fam20C, thereby inhibiting the deterioration of TNBC and preventing its progression. Taken together, these results suggest that compound 5k can be utilized as a novel Fam20C inhibitor, laying a foundation for the discovery of more small-molecule drugs for the treatment of TNBC in the future.
引用
收藏
页数:21
相关论文
共 50 条
[41]   Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment [J].
Sarlak, Saharnaz ;
Pages, Gilles ;
Luciano, Frederic .
CANCER TREATMENT REVIEWS, 2025, 136
[42]   Interaction of glaucocalyxin a with glutathione and thioredoxin reductase for triple-negative breast cancer treatment [J].
Duan, Dongzhu ;
Yang, Xing ;
Guo, Xiangyu ;
Li, Mi ;
Jin, Xiaojie ;
Wang, Le ;
Xiao, Jian ;
Wang, Xiaoling ;
Song, Peng .
BIOORGANIC CHEMISTRY, 2025, 161
[43]   Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer [J].
Qi, Yanfeng ;
Fu, Xueqi ;
Xiong, Zhenggang ;
Zhang, Haitao ;
Hill, Steven M. ;
Rowan, Brian G. ;
Dong, Yan .
PLOS ONE, 2012, 7 (02)
[44]   ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells [J].
Lim, Bora ;
Peterson, Christine B. ;
Davis, Alexander ;
Cho, Elin ;
Pearson, Troy ;
Liu, Huey ;
Hwang, Minha ;
Ueno, Naoto Tada ;
Lee, Jangsoon .
BIOMEDICINES, 2021, 9 (10)
[45]   Antiproliferation and apoptosis studies of estrone pharmacophores in triple-negative breast cancer [J].
Acheampong, Felix ;
Ostlund, Trevor ;
Mahnashi, Mater ;
Halaweish, Fathi .
CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 102 (05) :1050-1066
[46]   The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer [J].
Kaur, Sukhmandeep ;
Mendonca, Patricia ;
Soliman, Karam F. A. .
NUTRIENTS, 2024, 16 (15)
[47]   Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells [J].
Kim, Elizabeth M. H. ;
Mueller, Kelly ;
Gartner, Elaina ;
Boerner, Julie .
JOURNAL OF SURGICAL RESEARCH, 2013, 185 (01) :231-239
[48]   (+)-Dehydroabietylamine derivatives target triple-negative breast cancer [J].
Ling, Taotao ;
Tran, My ;
Gonzalez, Miguel A. ;
Gautam, Lekh Nath ;
Connelly, Michele ;
Wood, Rachael K. ;
Fatima, Iram ;
Miranda-Carboni, Gustavo ;
Rivas, Fatima .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 102 :9-13
[49]   Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells [J].
Howard, Cory M. ;
Estrada, Matthew ;
Terrero, David ;
Tiwari, Amit K. ;
Raman, Dayanidhi .
CANCERS, 2020, 12 (08) :1-18
[50]   Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer [J].
Raninga, Prahlad V. ;
Lee, Andy C. ;
Sinha, Debottam ;
Shih, Yu-Yin ;
Mittal, Deepak ;
Makhale, Ashwini ;
Bain, Amanda L. ;
Nanayakarra, Devathri ;
Tonissen, Kathryn F. ;
Kalimutho, Murugan ;
Khanna, Kum Kum .
INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (01) :123-136